Charles Roberts

Co-Founder, Chief Growth Officer

Charles Roberts, also known as Charles Campbell Roberts, is a medically trained serial biotech entrepreneur with a strong focus on the intersection of AI, systems biology, and preventative healthcare. Here are some key points about his background and roles:

Education and Training

He holds multiple degree-level qualifications, including a BSc in Psychology from University College London (2001), a degree in Medicine from the University of Dundee (2002), MRCS (Ed) from the Royal College of Surgeons of Edinburgh (2006), and an MSc from the University of Oxford (2014).1 2 3

Professional Roles

Freenome Holdings, Inc.: Co-founder, Chief Growth Officer, and previously the founding CEO (2014-2016). Freenome is a Bay Area biotech company focused on early cancer detection using multiomics platforms and has raised over $1.3 billion from prominent investors.1 2 3
Relation Therapeutics Ltd.: Co-founder and Chairman. This company is involved in health technology and has received significant funding, including a $60 million seed round in 2024.2 3 4
ARK Investment Management LLC: Chief Investment Strategist, a role he assumed in 2023. Here, he is involved in research and strategies for both public and private markets, with a focus on AI and multiomics.4

Other Ventures and Roles

Founder of Multiple Companies: He has co-founded several other companies, including Yourgene Health Plc, Agalimmune Ltd., Centauri Therapeutics Ltd., and a non-invasive prenatal testing company.2 3
Advisor and Consultant: He has advised various entities, including Oxford University's spin-out fund, OSI, Juvenescence, Anthem Digital Health group, and the X PRIZE Foundation.2 3

Research and Publications

Charles Roberts has published and co-published in several high-impact journals such as Nature Reviews Genetics, Nature Communications, and Briefings in Bioinformatics. He is also an author on several issued patents and a practitioner of deep learning.3

His LinkedIn profile, under the username 'charles-roberts-3200187', reflects his extensive experience and current roles in the biotech and investment sectors.5